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Background: Metastatic castration-resistant prostate cancer (mCRPC) and its treatment significantly affect
health-related quality of life (HRQOL). Our objectives were to evaluate and compare patient-reported outcome
(PRO) claims granted by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for 5
recently approved mCRPC treatments and to examine key characteristics, development, and measurement
properties of the PRO measures supporting these claims against current regulatory standards.
Methods: Five products approved for treatment of mCRPC by the FDA and the EMA (2010–2013) were examined:
enzalutamide, abiraterone, sipuleucel-T, cabazitaxel, and radium Ra 223 dichloride. United States (US) drug approval
packages and European Public Assessment Reports were reviewed. PRO claims in the US labels and European
Summaries of Product Characteristics and supporting measures were identified. For PRO measures supporting
claims, a targeted literature review was conducted to identify information on key characteristics and measurement
properties; this information was compared against FDA PRO guidance criteria.
Results: Nine PRO “claims” were granted across 4 of 5 products reviewed. The EMA granted more claims
(7 claims—4 for pain, 3 for HRQOL) than the FDA (2 claims, both for pain). The Brief Pain Inventory–Short Form
(BPI-SF) worst pain item supported most pain claims and was the only measure supporting US claims. EMA
pain claims were supported by BPI-SF worst pain (n = 2) and average pain (n = 1) items and the McGill Pain
Questionnaire Present Pain Intensity component (n = 1). EMA HRQOL claims were supported by the Functional
Assessment of Cancer Therapy–Prostate Module (n = 2) and the EuroQol 5 Dimensions with visual analogue scale
(n = 1). Pain and prostate cancer–specific HRQOL measures supporting claims met US regulatory standards for
construct validity, reliability, and responsiveness; these properties were strongest for the BPI-SF worst pain item. Only
the BPI-SF worst pain item has documented content validity in mCRPC.
Conclusions: PRO label claims were commonly granted across the mCRPC products reviewed. Among the
measures reviewed, only the BPI-SF worst pain item supported US label claims. The BPI-SF worst pain item is
recommended for pain assessment for the evaluation of new mCRPC treatments.
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Prostate cancer (PC) is the most commonly diagnosed
solid organ malignancy in the United States (US) and the
second-leading cause of cancer deaths among American
men [1]. These deaths are often the result of metastatic
castration-resistant prostate cancer (mCRPC), which his-
torically has had a median survival of fewer than 2
years [1].
More than 90% of patients with mCRPC develop bone
metastases [2]. Bone involvement in mCRPC can lead to
significant morbidity, which includes pain and skeletal-
related events such as spinal cord compression, patholo-
gical fractures, hypercalcemia of malignancy, requirement
for interventions such as bone surgery, or need for bone
radiation [2]. Other symptoms of mCRPC include an-
orexia, anxiety, constipation, diarrhea, sleep disturbance,
mucositis, nausea, peripheral sensory neuropathy, rash,
vomiting, and urinary symptoms [3]. Fatigue is another
dominant PC symptom and the most common adverse
event resulting from mCRPC treatment [4]. These disease
symptoms and noted side effects of treatment can sig-
nificantly affect health-related quality of life (HRQOL).
Therefore, patient-reported outcomes (PROs) are im-
portant to assess in patients with mCRPC to develop an
understanding of the patient-subjective experience with
disease and treatment; they are also particularly important
when new treatments have a modest impact on survival
[3,5]. In addition, a recent study by Miller and colleagues
found that achieving dual PRO claims in the US and the
European Union (EU) has led to increased market share
for oncology products in the US [6].
In 2004, two pivotal trials, TAX-327 and SWOG 9916,
supported the approval of docetaxel as the first mCRPC
treatment, in combination with prednisone, found to pro-
long median overall survival by approximately 3 months
when compared with the combination of mitoxantrone
and prednisone [7,8]. Consequently, docetaxel became the
standard first-line regimen in patients with mCRPC [9]. A
variety of chemotherapies, targeted therapies, and im-
munotherapies since have been developed and approved
for use in mCRPC, with the goal of improved efficacy
outcomes when compared with docetaxel [9]. Zytiga
(abiraterone), Jevtana (cabazitaxel), Xtandi (enzaluta-
mide), Xofigo (radium Ra 223 dichloride), and Provenge
(sipuleucel-T) were recently approved (2010–2013) by
both the US Food and Drug Administration (FDA) and
the European Medicines Agency (EMA) for the treatment
of mCRPC. In addition to survival, PRO endpoints were
included in clinical registration trials for each of these
newly approved products to assess HRQOL and other
concepts of importance to patients with mCRPC.
The objectives of this research were to evaluate and
compare PRO label claims granted by the FDA and the
EMA for these five recently approved mCRPC treatmentsand to examine the key characteristics, development, and
measurement properties of the PRO instruments for
which label claims were achieved against current regula-
tory standards for PROs [10]. The five recently approved
drugs were chosen because they reflect the most current
regulatory thinking. The research findings can be used
to inform the development of a PRO strategy for phase
2 and 3 clinical trials designed to support a product
label claim for a new treatment for mCRPC.
Methods
Identification of PRO label claims and supporting
measures
The website Drugs@FDA was searched to identify the
latest product label and drug approval package (DAP)
for abiraterone, cabazitaxel, enzalutamide, radium Ra
223 dichloride, and sipuleucel-T [11]. Relevant informa-
tion was retrieved from the Medical Review section of
each DAP. In addition, European Public Assessment Re-
port (EPAR), including the most recent version of the
Summary of Product Characteristics (SmPC) and scientific
discussion documents, were identified for each product
using the EMA website [12].
The labels and SmPCs were reviewed to identify PRO
label claims and the measures supporting them. DAPs
and EPARs were reviewed to determine any PRO mea-
sures that resulted in PRO claims but were not specifically
named in the label or SmPC. Any indication of PRO-
related comments by the reviewing division or the Study
Endpoints and Label Development (SEALD) group were
also noted when reviewing US DAPs and labels.
For analysis purposes, a PRO claim was defined as any
mention of a PRO measure or patient-reported endpoint
(whether or not the PRO measure was named; e.g., “pro-
portion of patients with pain palliation”) anywhere in the
product label or SmPC. A product with multiple analyses
and results described in the label or SmPC based on the
same PRO measure counted as a single claim. Each pro-
duct may have had more than one PRO claim. PRO label
claims were classified based on the following types: symp-
tom (pain), PC-specific HRQOL, and generic HRQOL.
Symptom-specific claims based on PRO measures focus-
ing solely on assessment of the concept of pain were clas-
sified as “symptom (pain).” HRQOL is a multidimensional
concept that represents the patient’s general perception of
the effect of illness and treatment on physical, psycho-
logical, and social aspects of life [10]. “Generic HRQOL”
claims were considered to be based on PRO measures
assessing HRQOL not specific to any particular disease.
“PC-specific HRQOL” claims were defined as being based
on measures focused on assessment of the impact of PC
on HRQOL.
Frequencies and cross-tabulation of label claim types
were calculated using Microsoft Excel 2010 (Excel). PRO
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also summarized descriptively in tabular format.Evaluation of selected PRO measures
For select PRO measures achieving label claims, targeted
searches of PubMed/Medline (back to 2003) were con-
ducted to identify relevant articles for review based on
abstracts in English. Additional desktop searches of in-
strument websites, the public-access version of PROQO-
LID, and an internal PRO instrument repository at RTI
Health Solutions (RTI-HS) were also conducted to iden-
tify relevant information and references, especially those
published prior to 2003 [13].
The primary goal of these searches was to identify
relevant information sources or publications for individ-
ual PRO measures, as available, describing instrument
development and psychometric properties (validity, reli-
ability, and responsiveness) in patients with mCRPC and
information on how to determine a clinically meaningful
change. We also sought to identify key characteristics of
each PRO measure supporting label claims including
constructs/subscales, the number of items, response scales,
and recall period. All relevant information identified was
recorded in tabular format in Excel.
The following information concerning the development
process was identified for each measure, as available, to in-
form the assessment of content validity: whether patients
with mCRPC were included during the development
process, whether input from clinicians or health care
professionals (HCPs) treating patients with mCRPC was
included during measure development, and whether a
literature review was conducted to identify items of im-
portance to patients with mCRPC during instrument
development.
When extracting relevant information from the source
documents for each measure of interest, content validity,
internal consistency, test-retest reliability, construct and
known-groups validity, and ability to detect change (also
referred to as responsiveness) were defined as per the
FDA PRO guidance [10].
Responsiveness is best assessed in the context of a the-
rapeutic intervention that has been shown to be effect-
ive. Therefore, to confirm PRO measure responsiveness
in patients with mCRPC, targeted searches were comple-
ted to identify any phase 2 or 3 randomized controlled
trials evaluating treatments for mCRPC that included
each relevant PRO measure, especially studies support-
ing an approved PRO label claim for an mCRPC product
of interest. Clinical trials that included the PRO mea-
sures but did not evaluate one of the five mCRPC treat-
ments of interest were excluded. Full-text articles were
preferred, but abstracts with relevant information were also
included. Two recent review articles were also searched toidentify studies cited demonstrating relevant PRO measure
responsiveness [3,9].
Finally, published information was sought for each PRO
measure of interest to identify recommendations for the
amount of change required to justify a clinically meaning-
ful change for an individual with mCRPC.
The available data identified regarding instrument cha-
racteristics, development, validation, responsiveness, and
interpretation for each relevant PRO measure were re-
viewed against FDA PRO guidance criteria, the highest
level of evidence currently required by a regulatory agency
to support medical product labeling claims [10]. Key con-
siderations in the evaluation of a PRO instrument’s ad-
equacy to support claims in medical product labeling
include satisfactory documented evidence of content val-
idity and established measurement properties (i.e., reliabil-
ity, validity, ability to detect change) in the target clinical
trial population. The FDA reviews documentation of the
PRO instrument development and evaluation in combin-
ation with clinical trial results to determine whether a la-
beling claim is substantiated [10]. Further critical aspects
considered by the FDA regarding the appropriate incorp-
oration of the PRO measure into the protocol and statis-
tical analysis plan include, but are not limited to, plans for
handling missing data, adjustment for multiplicity, and
plans for interpretation beyond statistical significance.
The EMA has not released a formal guidance docu-
ment related to PROs; instead, it has issued a reflections
paper that provides broad recommendations regarding
HRQOL evaluation, a specific type of PRO in the con-
text of clinical trials to support claims [14]. Although
there are many similarities in the requested information
for HRQOL measures (e.g., documentation of validation
in the target population; appropriate incorporation of
the PRO measure into the protocol and statistical ana-
lysis plan including, but not limited to, plans for hand-
ling missing data, adjustment for multiplicity, and plans
for interpretation beyond statistical significance), the
level of documentation is considerably less than that re-
quired by the FDA PRO guidance [10].
Results
Identification of PRO label claims and supporting
measures
Four of the five mCRPC products reviewed received one
or more PRO label claims (Table 1). Only sipuleucel-T
was not granted a PRO label claim by either the FDA or
the EMA.
Table 2 summarizes the type of PRO claim granted by
the EMA or the FDA for the products reviewed. A total
of nine PRO claims were granted across the four mCRPC
products that achieved claims. Pain claims were the
most common (n = 6), followed by HRQOL claims (n = 3
[PC-specific HRQOL, n = 2; generic HRQOL, n = 1]). The
Table 1 PRO label claims achieved in the US compared to the EU
Product (brand name/generic name) US approval year US product label claim(s) EU approval year EU SmPC claim(s)
Xtandi/enzalutamide 2012 Yes 2013 Yes
Zytiga/abiraterone 2011 Yes 2011 Yes
Jevtana/cabazitaxel 2010 No 2011 Yes
Xofigo/radium Ra 223 dichloride 2013 No 2013 Yes
Provenge/sipuleucel-T 2010 No 2013 No
EU = European Union; SmPC = Summary of Product Characteristics; US = United States.
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(n = 2) among the four reviewed products with claims.
The FDA granted only pain claims for two products,
enzalutamide and abiraterone. The EMA granted pain
claims (n = 4) for enzalutamide, abiraterone, and caba-
zitaxel and granted HRQOL claims (n = 3) for abira-
terone and Ra-223.
As shown in Table 3, the Brief Pain Inventory–Short
Form (BPI-SF) worst pain item supported the majority
of the pain claims and was the only measure supporting
US PRO claims. The EMA-approved pain claims were
supported by the BPI-SF worst pain item (n = 2), the
BPI-SF average pain item (n = 1), and the Present Pain
Intensity (PPI) component of the McGill Pain Question-
naire (MPQ) (n = 1). HRQOL measures supporting EMA-
approved claims included a PC-specific measure, the
Functional Assessment of Cancer Therapy–Prostate Mo-
dule (FACT-P) (n = 2), and a generic measure, the EuroQol
5 Dimensions (EQ-5D) questionnaire with visual analogue
scale (VAS) (n = 1).
Table 4 summarizes the PRO claim language granted
by the FDA and the EMA across the four mCRPC prod-
ucts with claims. All the PRO claims were identified in
the Clinical Studies section of the US labels and Clinical
Efficacy and Safety section of the EU SmPCs. The PRO
claims for enzalutamide in both the US and the EU were
limited to the description of baseline data for the BPI-SF
worst pain item. The only PRO claim in the US indicat-
ing positive data was the “time to opiate use result was
supported by a delay in patient reported pain progres-
sion” for abiraterone, based on the BPI-SF worst painTable 2 PRO claim types granted by the FDA or the EMA
Type of claim FDA-granted
claim (N = 5
products)
EMA-granted
claim (N = 5
products)
Total claims
(N = 5 products)




Generic HRQOL 0 1 1
Total claims 2 7 9
EMA = European Medicines Agency; FDA = Food and Drug Administration;
HRQOL = health-related quality of life.item. No other PRO claims were permitted in the US for
the products reviewed.
EU claims related to pain progression and pain res-
ponse were common to both abiraterone and cabazitaxel
SmPCs. The abiraterone SmPC had multiple results de-
scribed based on positive data from both the BPI-SF
worst pain item (including median time to pain progres-
sion [months], proportion [%] of patients with pain palli-
ation, proportion [%] of patients with pain progression,
and time [months] to pain progression at the 25th per-
centile) and the BPI-SF average pain item (reduction in
risk [%] of average pain intensity progression). In con-
trast, the cabazitaxel SmPC indicated that “there was no
statistical difference between both treatment arms in
pain progression and pain response” based on the PPI
scale from the MPQ. The abiraterone and radium Ra
223 dichloride SmPCs both included HRQOL claims
based on the FACT-P. Abiraterone’s claims were based
on both the risk (%) of and median time (months) to
FACT-P total score degradation, whereas radium Ra 223
dichloride’s claim was based on changes from baseline in
FACT-P total score. The radium Ra 223 dichloride SmPC
also included claim language based on changes from base-
line in the EQ-5D and VAS.
Evaluation of instrument properties for selected PRO
measures against FDA guidance criteria
Two targeted searches were conducted in PubMed/Med-
line: one search to identify literature describing the key
instrument characteristics, development, and validation
information for the BPI-SF worst pain item, BPI-SF ave-
rage pain item, MPQ PPI, and FACT-P; and the other
search to identify literature describing the responsive-
ness of these measures in clinical registration trials for
the five mCRPC treatments of interest.
The two PubMed/Medline searches identified a total
of 71 articles for review; of these, 65 were excluded be-
cause they did not contain relevant information, and 6
were included. Additionally, two papers cited in the re-
view articles examined, two papers obtained from the
RTI-HS PRO instrument repository, and one paper identi-
fied on an instrument developer’s website were included.
Eleven papers, in total, were reviewed and are sum-
marized. One published abstract was identified, and the
Table 3 PRO measures supporting label claims in the US and EU
Product (brand name name/
generic name)
PRO measure(s) supporting US
product label claim(s)
PRO measure(s) supporting EU SmPC claim(s)
Xtandi/enzalutamide BPI-SF worst pain itema BPI-SF worst pain itema
Zytiga/abiraterone BPI-SF worst pain item BPI-SF worst pain and average pain intensity items; FACT-P
Jevtana/cabazitaxel None PPI scale from the McGill-Melzack questionnaireb
Xofigo/radium Ra 223 dichloride None FACT-P
EQ-5D with VAS
Provenge/sipuleucel-T None None
BPI-SF = Brief Pain Inventory–Short Form; EU = European Union; EQ-5D with VAS = EuroQoL 5 Dimensions with visual analogue scale; FACT-P = Functional
Assessment of Cancer Therapy–Prostate Module; PPI = Present Pain Intensity; PRO = patient-reported outcome; SmPC = Summary of Product Characteristics;
US = United States.
aThe BPI was described in four different ways between the US label and EU SmPC for Xtandi (i.e., BPI, BPI-SF, BPI worst pain item and BPI-SF worst pain item). For
the purposes of PRO label claim analyses and given other consistencies between descriptions, we assumed the BPI-SF worst pain item was actually implemented
in the Xtandi studies for both the US and EU.
bThe McGill-Melzack questionnaire is also known as the McGill Pain Questionnaire (MPQ).
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vided by the authors upon request, is summarized. The
EuroQoL website also provided relevant information for
inclusion in this paper. Finally, key measurement charac-
teristics (e.g., number of items, recall period) for the four
measures were pulled from PROQOLID to supplement
information found in the papers reviewed. The informa-
tion identified for the four PRO measures of interest then
was evaluated against FDA guidance criteria [10] for PRO
measures intended to support labeling claims in the US.
The EQ-5D supported a PRO claim in the SmPC for ra-
dium Ra 223 dichloride but was excluded from review and
evaluation because it is a generic HRQOL measure used
broadly in most therapeutic areas to determine health util-
ity scores for economic modeling [15].
Table 5 summarizes the key characteristics and con-
tent validity for the PRO measures reviewed.
Key instrument characteristics
The BPI-SF is a pain-specific measure developed by
Charles Cleeland to assess patient-reported severity (or
intensity) of pain (4 items) and impact of pain on daily
functioning (11 items) in patients with cancer pain [16].
Two of the items on the BPI-SF pain severity subscale
assess worst pain in the past 24 hours and average pain
(recall period not specified), respectively. For all items
on this subscale, patients are asked to rate their pain on
an 11-point numeric rating scale with anchors of 0 (no
pain) and 10 (pain as bad as you can imagine). The worst
pain item’s brief recall period is favored by the FDA,
whereas the average pain item does not specify a recall
period and may be considered less favorable.
The PPI is a single item developed by Ronald Melzack
to measure patient-reported pain intensity with present
recall. The PPI is one component and an individually
scored subscale of the 20-item MPQ [17]. The PPI asks pa-
tients to rate their pain using a 6-point verbal rating scale(0 =No pain, 1 =Mild, 2 =Discomforting, 3 = Distressing,
4 = Horrible, 5 = Excruciating). The PPI is symptom-
specific, brief, and has a short recall period, all considered
favorable characteristics by the FDA [10].
The FACT-P is a 39-item questionnaire developed by
Dr. David Cella and colleagues at Functional Assessment
of Chronic Illness Therapy to assess patient-reported
HRQOL and PC-specific symptoms [18]. The FACT-P
consists of the 27-item Functional Assessment of Cancer
Therapy–General (FACT-G) and a 12-item PC subscale.
The 27 items in the FACT-G are grouped into four
domains: physical well-being, social/family well-being,
emotional well-being, and functional well-being. The
PC subscale assesses pain (3 items), urination problems (3
items), and sexual functions (2 items). In addition, it con-
tains items for weight loss, appetite, overall comfort, and
bowel movement. FACT-P items ask patients to recall
over the past 7 days and are rated using a 5-point Likert
rating scale (0 =Not at all; 1 = A little bit; 2 = Somewhat;
3 = Quite a bit; and 4 = Very much). Although multi-item
scales assessing HRQOL have been accepted for labeling
since the release of the draft PRO guidance by the FDA in
2006 (e.g., Soliris [eculizumab] and Letairis [ambrisentan]),
brief measures examining disease symptoms or function-
ing with short recall periods are preferred by the FDA,
and the majority of US label claims have been based on
these types of PRO measures [10,19,20].
Instrument development and content validity
Given the emphasis of the FDA PRO guidance on con-
tent validity, detailed information on the development of
each PRO measure of interest was sought to inform the
assessment of each measure’s content validity in patients
with mCRPC [10]. Although patients with mCRPC were
not included during initial development of the BPI-SF or
MPQ, Gater and colleagues evaluated the content vali-
dity of the BPI-SF “worst pain” and “average pain” items
Table 4 PRO claims granted by the FDA and the EMA
Product (brand name/
generic name)
US product label claim(s) EU SmPC Claim(s)
Xtandi/enzalutamide “Baseline data: 28% had a mean Brief Pain Inventory score
of≥ 4”
“28.4% had a mean Brief Pain Inventory score of≥ 4 (mean
of patient’s reported worst pain over the previous 24 hours
calculated for seven days prior to randomization).”
“P-value is derived from a log-rank test stratified by baseline
ECOG performance status score (0–1 vs. 2) and mean base-
line pain score (BPI-SF score < 4 vs. ≥ 4)”
Overall survival presented in a table by subgroup; one of the
subgroups was “Baseline mean pain score on BPI-SF
Question #3a” of < 4 compared to≥ 4
Zytiga/abiraterone Study 1 (baseline data): Study 302:
“45% had a Brief Pain Inventory-Short Form score of≥ 4
(patient’s reported worst pain over the previous 24 hours)”
“A score of 0–1 on Brief Pain Inventory-Short Form (BPI-SF)
worst pain in last 24 hours was considered symptomatic, and
a score of 2–3 was considered mildly symptomatic.”
Study 2:
“Baseline pain assessment was 0–1 (asymptomatic) in 66% of
patients and 2–3 (mildly symptomatic) in 26% of patients as
defined by the Brief Pain Inventory-Short Form (worst pain
over the last 24 hours).”
“Pain: Treatment with ZYTIGA significantly reduced the risk of
average pain intensity progression by 18% compared with
placebo (p = 0.0490). The median time to progression was
26.7 months in the ZYTIGA group and 18.4 months in the
placebo group.”
“The median time to opiate use for prostate cancer pain was
not reached for patients receiving ZYTIGA and was
23.7 months for patients receiving placebo (HR = 0.686; 95%
CI: [0.566, 0.833], p = 0.0001). The time to opiate use result
was supported by a delay in patient reported pain
progression favoring the ZYTIGA arm.”
“Time to degradation in the FACT-P (Total Score): Treatment
with ZYTIGA decreased the risk of FACT-P (Total Score)
degradation by 22% compared with placebo (p = 0.0028).
The median time to degradation in FACT-P (Total Score) was
12.7 months in the ZYTIGA group and 8.3 months in the
placebo group.”
Study 301:
“The proportion of patients with pain palliation was
statistically significantly higher in the ZYTIGA group than in
the placebo group (44% versus 27%, p = 0.0002). A
responder for pain palliation was defined as a patient who
experienced at least a 30% reduction from baseline in the
BPI-SF worst pain intensity score over the last 24 hours
without any increase in analgesic usage score observed at
two consecutive evaluations four weeks apart. Only patients
with a baseline pain score of≥ 4 and at least one post-
baseline pain score were analysed (N = 512) for pain
palliation.”
“A lower proportion of patients treated with ZYTIGA had
pain progression compared to patients taking placebo at 6
(22% versus 28%), 12 (30% versus 38%) and 18 months (35%
versus 46%). Pain progression was defined as an increase
from baseline of ≥ 30% in the BPI-SF worst pain intensity
score over the previous 24 hours without a decrease in
analgesic usage score observed at two consecutive visits, or
an increase of≥ 30% in analgesic usage score observed at
two consecutive visits.”
“The time to pain progression at the 25th percentile was 7.4
months in the ZYTIGA group, versus 4.7 months in the
placebo group.”
Jevtana/cabazitaxel None “Secondary endpoints include pain progression [assessed using
the Present Pain Intensity (PPI) scale from the McGill-Melzack
questionnaire and an Analgesic Score (AS)] and pain response
(defined as 2-point greater reduction from baseline median PPI
with no concomitant increase in AS, or reduction of≥ 50% in
analgesic use from baseline mean AS with no concomitant
increase in pain).”
“There was no statistical difference between both treatment
arms in pain progression and pain response.”
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Table 4 PRO claims granted by the FDA and the EMA (Continued)
Xofigo/radium Ra 223
dichloride
None “Health Related Quality of Life (HRQOL) was assessed in the
phase III ALSYMPCA study using specific questionnaires: the
EQ-5D (generic instrument) and the FACT-P (prostate cancer
specific instrument). Both groups experience a loss of quality
of life. Relative to placebo, the decline in quality of life was
slower for Xofigo during the on-treatment period as measured
by EQ-5D utility index score (−0.040 versus −0.109; p = 0.001),
EQ-5D self-reported Visual Analogue health status scores (VAS)
(−2.661 versus −5.860; p = 0.018) and the FACT P total score
(−3.880 versus −7.651, p = 0.006) but did not reach published
minimally important differences. There is limited evidence that
the delay in loss of HRQOL extends beyond the treatment
period.”
“The results from the phase III ALSYMPCA study regarding time
to external beam radiation therapy (EBRT) for pain relief and
fewer patients reporting bone pain as an adverse event in the
Xofigo group indicate a positive effect on bone pain.”
BPI-SF = Brief Pain Inventory–Short Form; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; EQ-5D = EuroQol 5 Dimensions; EU = European
Union; FACT-P = Functional Assessment of Cancer Therapy–Prostate Module; FDA = Food and Drug Administration; EMA = European Medicines Agency; HR = hazard
ratio; HRQOL = health-related quality of life; SmPC = Summary of Product Characteristics; US = United States.
aBPI-SF Question #3 asks about worst pain in the last 24 hours.
Table 5 Key characteristics and instrument development evidence supporting content validity
BPI-SF worst pain item BPI-SF average pain item PPI (from MPQ) FACT-P
Key characteristics
Type of measure Symptom: pain Symptom: pain Symptom: pain PC-specific HRQOL
Constructs/subscales Pain intensity (or severity):
worst paina









Plus PC subscale (12 site-specific
items to assess prostate related
“additional concerns”)
Number of items 1 1 1 39 (27 FACT-G; 12 PC specific)
Recall period Past 24 hours Unspecified Present Past 7 days
Response scale 0-10 NRS 0-10 NRS 0-6 VRS 5-point Likert scale
Instrument development: support for
content validity
Patients with mCRPC included in
development process
–/✓a –a –a –/✓b
Input from clinicians or HCPs treating
patients with mCRPC included in
development measure
– – – –
Items of importance to patients with
mCRPC identified from literature review
during instrument development
– – – –
BPI-SF = Brief Pain Inventory–Short Form; FACT-G = Functional Assessment of Cancer Therapy–General; FACT-P = Functional Assessment of Cancer Therapy—
Prostate Module; HCP = health care professional; HRQOL = health-related quality of life; mCRPC =metastatic castration-resistant prostate cancer; MPQ =McGill Pain
Questionnaire; NRS = numeric rating scale; PC = prostate cancer; PPI (from MPQ) = Present Pain Intensity component of the McGill Pain Questionnaire; VRS = verbal
rating scale.
✓= Yes, evidence identified; − = No evidence identified.
aGater and colleagues evaluated the content validity of the BPI-SF “average pain” and “worst pain” items (both assessed on a 0–10 numeric rating scale) in
cognitive debriefing interviews with 17 patients with mCRPC [21]. Results strongly supported content validity for the “worst pain item” in this population. However,
there was variability in patients’ interpretation of the “average pain” item, so results did not support the content validity of this item in patients with mCRPC. The
MPQ PPI (assessed on a 0–6 VRS) was also evaluated. Patients’ interpretation of the PPI item was variable, and they also had difficulty with the VRS [21].
bAccording to Esper and colleagues, eight individuals with PC contributed to item development, and 25 individuals with PC at various stages and 10 additional
patients with PC who had undergone radical prostatectomy completed and provided feedback on the first draft of the FACT-P [18]. However, the exact number of
patients with mCRPC included during development was not reported. Based on a personal communication with the instrument developer, Dr. David Cella, most
patients participating in the Esper study were men with early stage disease and only some had advanced, metastatic and castrate-resistant disease [18].
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as the MPQ PPI (assessed on a 0–6 verbal rating scale)
in cognitive debriefing interviews with 17 patients with
mCRPC [21]. Results of this study strongly supported
content validity for the “worst pain item,” whereas the
results did not support content validity for the “average
pain” item or the MPQ PPI item. Esper and colleagues
reported that a total of 43 individuals with PC were in-
volved in the development of the FACT-P [18]. Although
the exact number of patients with mCRPC included dur-
ing development was not reported in the publication,
Dr. David Cella, the FACT-P developer, indicated (per-
sonal communication, 2014) that most of the patients in
the Esper study were men with early stage disease, al-
though some had advanced, metastatic, and castration-
resistant disease. No further published information is
available on the content validity of the FACT-P in pa-
tients with mCRPC [18].
No evidence was identified that input from clinicians
or HCPs treating patients with mCRPC was included in
the development of any of the four measures reviewed,
nor were items of importance to patients with mCRPC
identified from the literature review during instrument
development.
In summary, only the BPI-SF worst pain item has do-
cumented content validity in patients with mCRPC, con-
sistent with FDA criteria.Table 6 Psychometric properties
Psychometric properties reported in published literature











Interpretation/clinically meaningful change established ✓g
References [16,23,31,34
BPI-SF = Brief Pain Inventory–Short Form; FACT-P = Functional Assessment of Cance
metastatic castration-resistant prostate cancer; MPQ =McGill Pain Questionnaire; NA
McGill Pain Questionnaire.
a✓= Yes, measurement property identified as evaluated based on patients with mC
patients with mCRPC.
bRobinson and colleagues reported acceptable (i.e., ICC > 0.70) test-retest reliability
individual average pain item [23].
cRobinson and colleagues reported nonacceptable (i.e., ICC < 0.70) test-retest reliabi
acceptable test-retest reliability (ICC = 0.85) in another trial of 93 patients with mCR
dConvergent and divergent validity established for the four-item FACT-P pain scale,
eEvidence of responsiveness of the PRO measure in one or more phase 2 or 3 rand
fPain progression and pain response endpoints did not differentiate between treatm
mCRPC [30].
gPatient scores ≥ 5 on the BPI-SF worst pain item are associated with significant and
adequacy of this cut point as an appropriate definition of pain progression in this p
FACT–P total score (score range: 0–156) [32].Psychometric properties
Table 6 summarizes the published evidence of instrument
reliability (internal consistency and test-retest reliability),
construct validity (convergent/divergent), known-groups
validity, responsiveness, and interpretation in patients with
mCRPC for the four PRO measures reviewed.
Reliability
Internal consistency was not applicable for assessment
for the BPI-SF worst pain and average pain items or the
PPI because these are single-item measures. Acceptable
internal consistency (i.e., Cronbach’s alpha above 0.70
but not higher than 0.95) was reported for the FACT-P,
with Cronbach’s alpha coefficients between 0.78 and 0.83
in patients with mCRPC [22,23].
Test-retest reliability was reported as acceptable (i.e.,
intraclass correlation coefficient [ICC] of 0.70 or greater)
for the BPI-SF worst pain item and FACT-P in two trials
evaluating treatment for patients with mCRPC [23,24].
Robinson and colleagues reported acceptable test-retest
reliability for the BPI-SF pain intensity scale (all 4 items
scored together; 0.73 and 0.90), but this information was
not available for the individual average pain item [23].
Construct and known-groups validity
A priori hypotheses were not identified to assess construct











– – ✓ g
,26,27] [16,23,34] [17,21,23,30] [18,23,28,32,34,26,29]
r Therapy–Prostate Module; ICC = intraclass correlation coefficient; mCRPC =
= not applicable; PPI (from MPQ) = Present Pain Intensity component of the
RPC; − = No, measurement property not identified as evaluated based on
for the BPI-SF pain intensity scale and worst pain item alone but not for the
lity of ICC = 0.56 for the PPI in one trial of 69 patients with mCRPC but
PC [23].
prostate cancer subscale, and total scale scores in patients with mCRPC [23].
omized controlled trials evaluating one of the mCRPC drugs of interest.
ent arms in the phase 3 registration study for cabazitaxel in patients with
meaningful impairments in patients with mCRPC, thus supporting the
opulation [31]; a clinically meaningful change of 6 to 10 was estimated for the
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validity was demonstrated for the BPI-SF worst pain and
average pain items, PPI, and FACT-P primarily through
Pearson correlations (r) between each of these instru-
ments to assess similar constructs using data from two tri-
als evaluating treatment for patients with mCRPC [23].
Correlation values were categorized as < 0.10, weak; 0.10-
0.50, moderate; and > 0.50, strong [25]. Pearson correla-
tions were strong between the BPI-SF worst pain and
average pain (r = 0.79; P < 0.006) items; there was a mod-
erate correlation between the BPI-SF worst pain item and
the FACT-P total score (r = −0.42; P < 0.006) and a strong
correlation with the PPI (r = 0.52; P < 0.006). The FACT-P
total score was also strongly correlated with the BPI-SF
average pain (r = 0.57; P < 0.006) item and moderately cor-
related with the PPI (r = 0.34; P < 0.006) [23]. No evidence
of divergent validity or known-groups validity was identi-
fied for any of the four PRO measures of interest in pa-
tients with mCRPC.
Ability to detect change (responsiveness)
Three of the four PRO measures of interest demonstra-
ted responsiveness in one or more phase 3 randomized
controlled trials evaluating recently approved treatment
for patients with mCRPC (Table 6). The BPI-SF worst
pain item was responsive in the published phase 3 regis-
tration studies supporting the approval of abiraterone
for patients with mCRPC [26,27]. The BPI-SF average
pain item was responsive in a single phase 3 registration
study supporting approval of abiraterone for patients
with mCRPC [27]. The FACT-P was also responsive in
both phase 3 registration studies for abiraterone and in
phase 3 studies for enzalutamide and docetaxel for pa-
tients with mCRPC [7,26,28,29]. However, based on the
studies reviewed, responsiveness was not demonstrated
for the PPI. Specifically, pain progression and pain res-
ponse endpoints did not differentiate between treatment
arms in the phase 3 registration study for cabazitaxel in
patients with mCRPC [30]. Thus, responsiveness is stron-
gest for the BPI-SF worst pain item and FACT-P followed
by the BPI-SF average pain item in clinical trials evaluating
recently approved treatments for patients with mCRPC.
Interpretation
Because statistical significance may be achieved with
small changes in PRO measures, understanding what con-
stitutes a clinically meaningful change on a PRO measure
can facilitate interpretation of clinical trial results for
treatment of mCRPC. Among the PRO measures re-
viewed, published information on the score interpret-
ation in patients with mCRPC was identified for the
BPI-SF worst pain item and FACT-P but not for the
BPI-SF average pain item or PPI. Based on treatment-
blinded data from 464 patients with mCRPC collectedas part of a multinational phase 3 clinical trial, Regnault
and colleagues confirmed that patient scores ≥ 5 on the
BPI-SF worst pain item are associated with significant
and meaningful impairments in patients with mCRPC,
thus supporting the adequacy of this cut point as an ap-
propriate definition of pain progression in this popula-
tion [31]. Cella and colleagues also conducted a study to
determine clinically meaningful changes for the FACT-P
[32]. By applying both anchor-based and distribution-
based methods to data from 809 patients with mCRPC
who participated in a phase 3 trial evaluating atrasentan,
a clinically meaningful change of 6 to 10 was estimated
for the FACT-P total score (score range: 0–156) [32].
Discussion
PRO label claims in the US and the EU for mCRPC products
This review provides a critical evaluation and compari-
son of PRO claims approved by the FDA and the EMA
for five recently approved products for mCRPC. Some
concordance was seen between the FDA and the EMA
for pain claims granted to enzalutamide and abiraterone
based on the BPI-SF worst pain item. Baseline BPI-SF
worst pain item data were included in both the US labels
and EU SmPCs for enzalutamide and abiraterone. This
concordance in the acceptance of pain claims may be
explained in part by the fact that patient-assessed core
symptoms of a disease such as pain are well-accepted
primary and secondary efficacy endpoints in registration
trials, according to the EMA reflection paper on HRQOL
measures [14]. Similarly, the FDA PRO guidance high-
lights the assessment of pain intensity using a single-item
measure as an obvious way to measure the impact of
treatment on pain [10]. Furthermore, the FDA guidance
for industry on cancer clinical trial design cites symptoms
as a direct efficacy endpoint that can be used to support
product approval [33].
However, even for the generally accepted concept of
pain, there was still some discordance between the FDA
and the EMA in the claim language allowed for mCRPC
products reviewed. The primary difference in claim lan-
guage between the US label and the EU SmPC for abira-
terone was that the US label focused on the opiate use
change, which was supported by the delay in pain pro-
gression, whereas the EU SmPC mentioned the time to
pain progression more directly. The EMA also granted
additional claim language in the SmPC for abiraterone,
including “time to pain degradation,” “proportion of pa-
tients with pain palliation,” and “proportion of patients
with pain progression” based on the BPI-SF worst pain
item. No further claims were granted in the US label for
this product. This discordance may be explained in part
by the FDA’s comments within the abiraterone DAP:
“Other secondary endpoints measured but not listed and
not evaluated in the review included proportion of
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analgesic score and time to pain progression…Reasons
for not including them in the review are as follows: only
a portion (<50%) of patients had data for the endpoints
not listed as key secondary endpoints; measuring the en-
dpoints was less objective, and their regulatory accept-
ability had not been evaluated by the Agency in terms of
reliability, validity, ability to detect change, and interpret-
ability in the study patient population; no pre-specified
plan for multiple comparisons adjustment; changes in
these endpoints do not constitute a basis for marketing
approval or disapproval of abiraterone acetate for the pro-
posed indication” [11].
Notably, a recent communication prepared by the FDA
highlighted the following challenges in pain palliation
measurement in cancer clinical trials [34]:
 Pain intensity and analgesic use assessment tools
must be demonstrated to be reliable, valid, and
sensitive to changes over time, consistent with FDA
PRO guidance criteria.
 Enrollment eligibility criteria should ensure that
patients are experiencing pain that is attributable to
cancer at baseline.
 The mode of data collection (e.g., paper, electronic,
internet, interactive voice response system, or
interviewer-administered) must demonstrate
measurement properties in keeping with the PRO
guidance principles.
 Optimal timing for pain and analgesic assessment is
over several consecutive days (e.g., daily over the
7-day period prior to a scheduled study visit).
 A pain palliation responder should be defined using
both pain and analgesic use criteria, incorporating
an analysis of tumor response that will support
evidence of pain palliation response.
 There is a risk of missing data and inadvertent
unblinding
Basch and colleagues stress the critical importance of
tracking analgesic use with a content-valid analgesic log
to ensure that pain palliation observed is truly the result
of the treatment being studied rather than the result of
an increase in analgesic use [34]. Furthermore, the anal-
gesic log should be administered using the same sche-
dule and recall period (e.g., past 24 hours) as the pain
intensity assessment during clinical studies evaluating
treatment. FDA feedback on the abiraterone DAP and
Basch and colleagues’ [34] publication regarding assess-
ment of pain palliation in cancer clinical trials highlight
the many factors considered by the FDA when conside-
ring pain claims for a new cancer product.
Although the EMA granted additional pain claims to
abiraterone based on the BPI-SF average pain item andto cabazitaxel based on the PPI, similar claims for these
products were not granted by the FDA for these PRO
measures. Based on publicly available information provi-
ded in the DAP for cabazitaxel, the following comments
were made by FDA reviewers during the end-of-phase-2
meeting (EOP2) in response to questions submitted by
the sponsor regarding the PPI and pain assessment: “We
recommend that you submit the final version of the PPI
and the AS [analgesic score] in the exact format it is ad-
ministered in your protocol with instructions on how
the instrument will be administered, directions explain-
ing how scores will be derived, and how the statistical
analyses will be applied; open-label data are only appro-
priate for labeling if results are convincing and conclu-
sive; pain intensity should be assessed at screening, and
then continued eligibility by pain score should be veri-
fied at baseline (i.e. before randomization/dosing); pain
intensity should then be recorded daily, over the dur-
ation of the trial. There should also be evidence of effi-
cacy over the entire duration of treatment; assessment of
the ‘worst pain’ will provide more reliable results than
‘average pain’ over 24 hours.” However, it should be no-
ted that the EOP2 meeting for cabazitaxel took place in
2006 and does not appear to represent the most current
thinking by the FDA regarding pain assessment. As dis-
cussed earlier by Basch and colleagues, daily collection
of pain and analgesic assessment for 7 consecutive days
prior to an office visit is recommended over continuous
daily collection of pain [34]. This recommendation is
likely due to higher patient burden and higher noncom-
pliance with continuous daily collection over the length
of the study period. Furthermore, the DAP for cabazi-
taxel indicated that the most frequent and most severe
protocol violations for the phase 3 registration study
were for missing pain assessments or analgesic scores,
with less than 50% of each treatment group reporting ana-
lyzable data. Although similar explanations from FDA re-
viewers were not available in the abiraterone DAP, the
FDA’s stated preference for the evaluation of “worst pain”
over the past 24 hours within the cabazitaxel DAP may
also partly explain why the claim was not granted for abir-
aterone based on the BPI-SF “average pain” item.
The largest area of discord identified between the EMA
and the FDA was for HRQOL claims. HRQOL claims
were granted by the EMA for both abiraterone (“time to
degradation in FACT-P total score”) and radium Ra 223
dichloride (“Relative to placebo, the decline in quality of
life was slower for Ra-223 during the on-treatment period
as measured by EQ-5D utility index score [−0.040 ver-
sus −0.109; p = 0.001], EQ-5D self-reported VAS [−2.661
versus −5.860; p = 0.018], and the FACT-P total score
[−3.880 versus −7.651, p = 0.006] but did not reach pub-
lished minimally important differences. There is limited
evidence that the delay in loss of HRQOL extends beyond
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products were not granted by the FDA.
Comments by FDA reviewers found within the radium
Ra 223 dichloride DAP may provide some insight into
why a HRQOL claim was not granted by the FDA for
this product. Specifically, the reviewer comments on the
PRO results from the key pivotal trial for radium Ra 223
dichloride stated that “FACT-P and EQ-5D total scores
showed a slight improvement for patients receiving Ra-
223 when compared to placebo. When evaluated by visit,
the statistical significance in the difference between groups
decreased over time. Whether this was due to the loss of
anti-cancer effect of Ra-223 with time or was due to de-
creased data completion rates is not known, although both
are likely contributors. The FDA SEALD cites limitations
specific to the current Ra-223 application including small
number of assessments (maximum of 4 for FACT-P), low
rate of completion at week 24+ as well as a small observed
magnitude of treatment effect. Despite the limitations in
choice of instrument, frequency of assessments and com-
pleteness of data, the quality-of-life results are supportive of
the overall application in that, on average, the available data
appear to trend toward an improvement in the Ra-223 arm
and do not show a detriment to quality of life measures or
pain in patients treated with Ra-223 when compared to
placebo.” Similar comments from FDA reviewers were not
available within the abiraterone DAP to further explain
why HRQOL claims were not granted for this product.
As demonstrated by the SmPC language for both caba-
zitaxel and radium Ra 223 dichloride, the EMA provided
more comprehensive coverage of both the positive and
negative PRO outcomes from the registration studies for
these products, whereas negative PRO outcomes were
discussed within the DAP but did not translate into label
language in the US.
The results of our research on PRO label claims for
mCRPC products recently approved in the US and the
EU further support the conclusions from several earlier
studies with similar objectives [10,35-37]. Demuro and
colleagues’ comparison of PRO label claims granted from
2006 to 2010 for new drug entities or biologic licensed
agents by the FDA and the EMA indicated that the
EMA is more likely than the FDA to grant PRO claims
and typically does so for higher-order constructs (e.g.,
HRQOL), whereas PRO claims in the US are most often
limited to those based on symptom improvement [19].
Similar findings also resulted from earlier research by
Coombs and colleagues when PRO claims in the US and
the EU were compared for oncology products [37].
Evaluation of instrument properties for selected PRO
measures against FDA guidance criteria
Of the measures evaluated, the BPI-SF worst pain item
has the strongest measurement properties in patientswith mCRPC. Most importantly, content validity has
been established in this population, a key criterion ne-
cessary for FDA acceptance in supporting labeling claims.
Furthermore, although evidence of known-groups validity
was not identified for this measure, test-retest reliability,
construct validity, and responsiveness have all been es-
tablished in patients with mCRPC [27,34]. Other key
strengths of this measure include the brief (24-hour) recall
period; the single-item assessment (low burden on pa-
tients to complete); the 11-point numeric rating scale,
which is well-accepted by patients, clinicians, and the
FDA; and information available to assist interpretation of
clinical trial results in patients with mCRPC with bone
metastases [31]. Based on this evidence and the ability to
achieve successful labeling claims of “delay in pain pro-
gression” for enzalutamide and abiraterone in both the US
and the EU, as well as additional claims in the EU for
“time to pain degradation,” “proportion of patients with
pain palliation,” and “proportion of patients with pain pro-
gression,” the BPI-SF worst pain item is recommended for
future evaluation of pain in trials evaluating treatment for
patients with mCRPC and for pursuit of similar labeling
claims in both the US and the EU.
The identified evidence in support of the BPI-SF aver-
age pain item is weaker when compared with FDA PRO
guidance criteria. Without documented evidence of con-
tent validity in patients with mCRPC, the FDA is unlikely
to grant PRO claims based on this single item. However,
the BPI-SF average pain item is recommended for pub-
lications supporting future FDA-approved products for
mCRPC and may achieve EMA-approved SmPC claims if
the data are convincing.
Of the three pain measures evaluated, the PPI com-
ponent of the MPQ has the least evidence to support
its future use in clinical trials evaluating mCRPC treat-
ments. When considering evaluation of pain in pa-
tients with mCRPC and if the desire is to achieve a
product label claim in the US or the EU, the PPI is
not recommended.
The FACT-P was the only HRQOL measure evaluated
against FDA PRO guidance criteria. Key strengths for
the FACT-P are established reliability (test-retest and
internal consistency), construct validity, known-groups
validity, responsiveness, and established definition for
clinically meaningful changes to assist with interpret-
ation in clinical trials evaluating patients with mCRPC
[32]. In particular, the FACT-P was responsive in both
phase 3 registration studies for abiraterone as well as
phase 3 studies for enzalutamide and docetaxel for pa-
tients with mCRPC but was less responsive in the regis-
tration study for radium Ra 223 dichloride described in
the SmPC [7,28,29,34]. Based on further examination of
the two EMA-approved SmPCs that included FACT-P
claims, there was clear positive claim language favoring
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degradation” and “time to degradation in FACT-P total
score,” whereas the analysis of change from baseline in
registration studies for radium Ra 223 dichloride re-
sulted in an SmPC claim that scores on this measure
did not reach the published minimum important differ-
ence. Given the limitation on content validity for the
FACT-P in patients with mCRPC, this measure is not
recommended to support US labeling claims for future
products. Because the FACT-P is validated and clearly
very responsive in studies evaluating treatment for
mCRPC, the FACT-P should still be considered for the
evaluation of PC-specific HRQOL to provide data for
US publication and support of SmPC claims in the EU.
More recently, the National Comprehensive Cancer
Network FACT Prostate Symptom Index-17 (NCCN-
FACT FPSI-17), a new prostate symptom index, was de-
veloped based on qualitative input from patients with
advanced (stage 3 and 4) castration-resistant PC, which
can be used to examine the effectiveness of noncurative
treatments in advanced PC [38]. Although the NCCN-
FACT FPSI-17 appears to have initial evidence of con-
tent validity, reliability, and construct validity in patients
with mCRPC, publications documenting its responsive-
ness in studies evaluating treatment for patients with
mCRPC are currently not available [38]. Once additional
studies are completed to further validate this measure
and establish responsiveness, it may potentially be con-
sidered for inclusion in future studies for treatment of
mCRPC designed to obtain US labeling claims focused
on PC symptom improvement, provided all FDA PRO
guidance criteria beyond content validity are also suffi-
ciently met in this population.
Notably, the concept of fatigue, a prevalent disease-
and treatment-related symptom of patients with mCRPC,
was measured using a fatigue-specific PRO measure (Brief
Fatigue Inventory) in registration trials for both abirater-
one and enzalutamide based on information provided
in each product’s DAP and EPAR [4]. However, neither
the FDA nor the EMA granted a fatigue claim. This
finding is not surprising given the recent views on fa-
tigue assessment expressed by an FDA representative
that fatigue is a multidomain concept not measurable
with a single item; it is believed that patients do not
use the term “fatigue”; problems with instrument con-
tent validity have not allowed conclusion of benefit;
and, finally, a clear link between fatigue and the disease
or treatment has not been found [39]. To address these
concerns, a consortium research project entitled Patient-
Reported Outcomes of Fatigue–Cancer has been estab-
lished “to define cancer related fatigue and determine
how it should be measured from a patient perspective”
[40]. The Cancer Fatigue–Symptom Severity Assess-
ment, a new multidimensional fatigue measure, hasbeen developed out of this consortium, is currently un-
dergoing psychometric validation, and is planned for drug
development tool qualification by the FDA [40]. This
measure may eventually be accepted by the FDA and the
EMA to support fatigue-specific PRO labeling claims for
new cancer products.
There are some notable limitations to our research.
First, although this study included the majority of re-
cently approved products for mCRPC, not all mCRPC
products were included [10]. Second, any PRO measures
included in clinical trials for mCRPC products reviewed
and mentioned in the DAP or EPAR for a product but
not resulting in US label or EU SmPC claims were
excluded from this review. Third, our review of regu-
latory feedback during the approval process for each
of the products was limited to the information that
was made publicly available on the FDA and EMA
websites. The drug manufacturers may possess add-
itional proprietary information that was not included.
Finally, the nature of our literature searches to iden-
tify the desired information supporting each PRO mea-
sure of interest was targeted rather than systematic.
Thus, it is possible that other information exists either
to support or refute the information presented in this
paper.
Conclusions
Our research findings can be used to inform the devel-
opment of a PRO strategy for phase 2 and 3 clinical tri-
als designed to support a product label claim for a new
mCRPC treatment. The BPI-SF worst pain item is recom-
mended for use in combination with analgesic use assess-
ment to evaluate pain progression and pain palliation.
Based on the demonstrated content validity in patients
with mCRPC and documented measurement properties in
this population, as well as the recent claims achieved for
enzalutamide and abiraterone, the BPI-SF worst pain item
alone may be supportive of future PRO-related claims in
both the US and the EU.
Assessment of PC-specific HRQOL using the FACT-P
to achieve time to FACT-P total score degradation claims
may continue to be accepted by the EMA and incor-
porated into EU SmPCs, whereas FACT-P data are re-
commended only for publication purposes in the US.
An mCRPC symptom index meeting all FDA PRO guid-
ance criteria, including content validity, likely has a greater
chance of supporting both US label and EMA SmPC
claims. The EQ-5D is recommended for PRO strategy
development for any new mCRPC treatment to iden-
tify health utility values for comparison across diseases.
EQ-5D with VAS data may also be used to support
SmPC claims in the EU; however, in the US, these
data are recommended for publication rather than label
claims. Finally, fatigue is another important disease- and
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should be considered for assessment in future clinical tri-
als using a validated assessment. Further work is needed
in this area to increase the likelihood of successful fatigue-
specific product label claims for mCRPC products in the
US and the EU.
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